Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism
- PMID: 22371808
- PMCID: PMC3284079
- DOI: 10.5114/aoms.2010.14476
Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism
Abstract
Introduction: The influence of demographic and clinical factors on the outcome of (131)I therapy in hyperthyroid patients has been examined, based on a retrospective evaluation of results obtained in patients submitted to (131)I treatment at the Department of Nuclear Medicine and Oncological Endocrinology, Medical University of Lodz (Province Hospital, Zgierz). The goal of the study was to analyse such factors as the age and sex of patients, disease duration, as well as the hormonal status before (131)I application, which could have an influence on the effects of therapy with radioiodine (131)I.
Material and methods: The study involved 500 randomly selected patients with hyperthyroidism, treated with (131)I radioiodine. The following 3 groups were defined: group 1 - patients with multinodular goitre (MNG), n = 200; group 2 - patients with a single autonomous nodule of the thyroid (AFTN), n = 100; group 3 - patients with Graves' disease (GD), n = 200. The local ethics committee (in the Polish Mother's Memorial Hospital - Research Institute, Lodz) approved the study.
Results: The obtained results indicate that the efficacy of therapy with (131)I applied in patients with MNG, AFTN and GD does not depend on either patient sex or patient age. The length of antithyroid treatment before (131)I therapy onset does not appear to have any effect on the therapy outcome, and the baseline thyrotropin concentration seems to be significant only in the case of GD.
Conclusions: The analysed demographic factors do not affect the outcome of (131)I therapy in hyperthyroidism.
Keywords: 131I radioiodine therapy; hyperthyroidism; thyroid.
Similar articles
-
Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs.Neth J Med. 1999 Nov;55(5):215-21. doi: 10.1016/s0300-2977(99)00066-2. Neth J Med. 1999. PMID: 10593131
-
Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country.World J Surg. 2007 Feb;31(2):306-12; discussion 313. doi: 10.1007/s00268-006-0572-9. World J Surg. 2007. PMID: 17219271
-
One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.Panminerva Med. 2000 Dec;42(4):241-5. Panminerva Med. 2000. PMID: 11294085
-
Hyperthyroidism. Current treatment guidelines.Drugs. 1998 Apr;55(4):543-53. doi: 10.2165/00003495-199855040-00005. Drugs. 1998. PMID: 9561343 Review.
-
TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.Exp Clin Endocrinol Diabetes. 2004 Apr;112(4):171-4. doi: 10.1055/s-2004-817930. Exp Clin Endocrinol Diabetes. 2004. PMID: 15127319 Review.
Cited by
-
Effectiveness of Radioiodine Treatment for Toxic Nodular Goiter.Mol Imaging Radionucl Ther. 2015 Oct 5;24(3):100-4. doi: 10.4274/mirt.48378. Mol Imaging Radionucl Ther. 2015. PMID: 27529884 Free PMC article.
-
Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I-: a retrospective study.BMC Endocr Disord. 2020 Jun 1;20(1):77. doi: 10.1186/s12902-020-00551-2. BMC Endocr Disord. 2020. PMID: 32487052 Free PMC article.
-
Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.Med Sci Monit. 2021 Jan 26;27:e928796. doi: 10.12659/MSM.928796. Med Sci Monit. 2021. PMID: 33497370 Free PMC article.
-
Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.Nucl Med Commun. 2018 Jan;39(1):16-21. doi: 10.1097/MNM.0000000000000770. Nucl Med Commun. 2018. PMID: 29040161 Free PMC article.
References
-
- Marinelli LD, Quinby EH, Hine GJ. Dosage determination with radioactive isotopes. Am J Roentgenol. 1948;59:260–81. - PubMed
-
- Als C, Baer HU, Glaser C, Roesler H. Choice of therapy in unifocal functional autonomy of the thyroid gland with hyperthyroidism. Schweiz Med Wochenschr. 1997;127:891–8. - PubMed
-
- Barrington SF, O'Doherty MJ, Kettle AG, et al. Radiation exposure of families of outpatients treated with radioiodine (iodine – 131I) for hyperthyroidism. Eur J Nucl Med. 1999;26:686–92. - PubMed
-
- Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S471–8. - PubMed
-
- Guhlmann CA, Rendl J, Börner W. Radiojodtherapie der funktionellen Autonomie und des M. Basedow. Nucl Med. 1995;34:20–3. - PubMed
LinkOut - more resources
Full Text Sources